Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview for even bigger and better gains to come.

Today, we've listed three stocks that made some of the biggest upward moves over the past month, which we'll pair with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.

Stock

30-Day % Change

CAPS Rating
(out of 5)

Pure Bioscience (Nasdaq: PURE)

76.2%

*

Borders Group (NYSE: BGP)

59.5%

*

Celldex Therapeutics (Nasdaq: CLDX)

29.0%

**

30-day % change from March 12 to April 12.

As the markets whipsaw to changes in consumer sentiment, there will be weeks like this one where we see gains that are exceptionally ahead of the pace of the movers and shakers of prior weeks. So before we get shaken out again, let's see why the CAPS community thinks some of these companies might continue to outperform the market.

A mighty temblor
It's not pure science fiction, but Pure Biosciences has a unique product that relies upon a new molecular entity called silver dihydrogen citrate, or SDC, which it will make into a hard-surface sanitizer for use in restaurants, homes, and medical facilities, among other things. Aside from competing against much larger competitors Clorox (NYSE: CLX) or DuPont (NYSE: DD), which also produce hard-surface sanitizers, Pure Biosciences faces the challenge of its base ingredient being silver, with fluctuations in price likely to wreak havoc on costs. These days that means lower margins.

The catalyst that drove Pure higher -- EPA registration of its sanitizer that will allow it to launch a product -- is but the first step on an arduous journey. Highly rated CAPS All-Star TSIF agrees things look better for the company than they did previously, but there are still a host of hurdles that don't justify the huge leap in value it has witnessed:

All in all, I would say things are looking "better" for [Pure Biosciences], but their sudden reach into the $100 Million market cap. [Pure] faces a host of other well known and better positioned players in this arena. With 23 employees and minimal production capabilities and a minimal sales force, [Pure] will need to continue to partner up at a discount, ramp up, dilute, and settle in for the long haul. Based on previous market adoption of thier other products earlier this year, [Pure] will not be a high flyer in a short period of time.

But you can tell us whether this growth opportunity is fact or fiction on the Pure Biosciences CAPS page, where two-thirds of those who have rated the company think the story thus far is a fairy tale.

Still feeling the aftershocks
Bookseller Borders Group has been clinging to life by its fingernails in recent months; even the entrance of a hero in the form of billionaire investor Bill Ackman of Pershing Square Capital Management doesn't make Borders' story much of a page-turner.

It might have been able to survive the threat Amazon.com's (Nasdaq: AMZN) Kindle posed, or even rival Barnes & Noble's (NYSE: BKS) e-reader, the Nook, but DarthMaul09 says Borders just won't be able to withstand the onslaught to its operations that the arrival of the iPad heralds:

The Kindle was not much of a threat, but the iPad may be a death blow, especially with Amazon's growing book store and iTunes library. If it wasn't for the partnered coffee shops bringing in business, [Borders] would probably not be in existence today. But how long can you live on the impulse buying of coffee drinkers?

Let us know on the Borders Group CAPS page whether this closes a chapter in the bookseller's story.

Buying growth
There's been no specific news that has sent Celldex Therapeutics higher this past month, other than its earnings report that showed a wider loss than a year ago on acquisition costs. While the news initially sent the stock price lower, it's the acquisition that could ultimately propel Celldex higher.

Celldex is a cancer drug developer and its purchase of CuraGen gives it a drug conjugate in phase 2 trials for breast cancer as well as a portfolio of 10 other therapies in development. That gives CAPS member malcifar confidence Celldex will be a good investment:

They have a lots of exciting things going on in multiple ongoing trials and have a history of wowing investors (and causing a significant jump in stock price) at the asco conferences. Even if they don't wow investors to immediately push past the $10 mark, its still a good long term investment based on their current pipeline and the hopes of future partnerships.

Shake, rattle, and roll
With these stocks shaking the market this past month, it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

Amazon is a Motley Fool Stock Advisor recommendation. Clorox is an Income Investor pick.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. You can shake, rattle, and roll The Motley Fool's disclosure policy, but it still won't break.